Try our beta test site

TMC114-C211: Trial of an Investigational Protease Inhibitor TMC114 With Ritonavir ("TMC114/r") in HIV-1 Infected Patients Who Have Never Been Treated With Antiretroviral Medications.

This study has been completed.
Information provided by (Responsible Party):
Tibotec Pharmaceuticals, Ireland Identifier:
First received: November 22, 2005
Last updated: June 25, 2013
Last verified: June 2013
The purpose of this study is to compare the efficacy, safety and tolerability of TMC114/r versus Kaletra (a combination pill of lopinavir and ritonavir, ("lpv/rtv") in HIV-1 infected patients who have never been treated with anti-retroviral medications (referred to as "treatment-naïve" patients).

Condition Intervention Phase
Drug: TMC-114/RTV
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase III Randomized, Controlled, Open-label Trial to Investigate the Antiviral Activity, Tolerability and Safety of TMC114/r in Treatment- Naive HIV-1 Infected Patients.

Resource links provided by NLM:

Further study details as provided by Tibotec Pharmaceuticals, Ireland:

Primary Outcome Measures:
  • Confirmed Virologic Response defined as a Viral Load < 50 copies/mL at Week 48 [ Time Frame: 48 weeks ]

Secondary Outcome Measures:
  • Evaluation of safety, tolerability, and durability of efficacy over 96 weeks of treatment [ Time Frame: 192 weeks ]

Enrollment: 692
Study Start Date: September 2005
Study Completion Date: May 2012
Primary Completion Date: June 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 002
TMC-114/RTV two 400 mg tablets of TMC114 + one 100 mg capsule of RTV daily for max. 192 weeks
Drug: TMC-114/RTV
two 400 mg tablets of TMC114 + one 100 mg capsule of RTV daily for max. 192 weeks
Active Comparator: 001
LPV/RTV 400/100 mg twice daily or 800/200 mg daily depending on the country for max. 192 weeks
400/100 mg twice daily or 800/200 mg daily depending on the country for max. 192 weeks

Detailed Description:

This is a randomized, controlled, open-label trial to investigate the antiviral activity, tolerability and safety of TMC114/r) versus lpv/rtv in treatment-naive HIV-1 infected patients. Six hundred sixty treatment-naïve HIV-1 infected patients will be randomized in a 1:1 ratio to either 800/100 mg of TMC114/r once daily, or a total daily dose of 800/200 mg of lpv/rtv. All patients will take TMC114/r or lpv/rtv in combination with an NRTI background of Truvada (a combination pill of tenofovir and emtricitabine, "TDF/FTC"). The trial will consist of a screening period of approximately 14 to 28 days and a 96-week treatment period, followed by a 4-week follow-up period. The anti HIV-1 therapy initiated at baseline cannot be changed until the end of the treatment period. After the end of the treatment period (maximum of 96 weeks), patients will be followed for an additional 4 weeks to follow-up on any adverse events or laboratory abnormalities until resolution. Patients who fail either virologically or due to intolerance from the TMC114/r or lpv/rtv therapy, as judged by the investigator, or who meet one of the withdrawal criteria will be withdrawn from the trial and may have the opportunity to participate in the rollover phase of the trial.

The primary efficacy parameter is virologic response defined as a confirmed viral load < 50 copies/mL at Week 48 the objective of this study is to establish non-inferiority of TMC114/r versus lpv/rtv in terms of virologic response at Week 48 using a non-inferiority margin of 12%. To test this hypothesis, a two-sided 95% confidence interval (CI) of the difference in response rate between TMC114/r and lpv/rtv will be derived: If the lower bound of the CI exceeds -12%, non-inferiority will be concluded. Patients will take oral doses for up to 96 weeks of either 800/100mg of TMC114/r 1x/day or 800/200mg of lpv/rtv once daily, each in combination with TDF/FTC. (The 400/100 mg 2x/day dose of lpv/rtv will be used where the 1x/day use of lpv/rtv is not approved).


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with documented HIV-1 infection
  • Screening plasma HIV-1 RNA >= 5000 copies/mL
  • Patients qualify for treatment initiation based on the investigator's assessments and/or according to treatment guidelines
  • Patients who can comply with the protocol requirements
  • General medical condition, in the investigator's opinion, does not interfere with the assessments and the completion of the trial.

Exclusion Criteria:

  • Presence of any currently active AIDS defining illness or receiving treatment for primary HIV infection
  • Life expectancy of less than 6 months
  • Previous or current use of antiretroviral medications (ARVs) for the treatment of HIV-infection or hepatitis B infection with anti-HIV activity
  • Female -patients who are pregnant or breast-feeding, or are of childbearing potential without use of effective non-hormonal birth control methods or not willing to continue practicing these birth control methods for at least 30 days after the end of the treatment period
  • -patients with a grade 3 or 4 laboratory abnormality as defined by DAIDS grading, or a calculated creatinine clearance (CLCr) < 70 mL/min
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00258557

  Hide Study Locations
United States, Arizona
Phoenix, Arizona, United States
United States, California
Beverly Hills, California, United States
Long Beach, California, United States
Los Angeles, California, United States
Sacramento, California, United States
San Francisco, California, United States
United States, District of Columbia
Washington, District of Columbia, United States
United States, Florida
Fort Lauderdale, Florida, United States
Jacksonville, Florida, United States
Miami Beach, Florida, United States
Miami, Florida, United States
Orlando, Florida, United States
Safety Harbor, Florida, United States
Tampa, Florida, United States
Vero Beach, Florida, United States
United States, Maryland
Baltimore, Maryland, United States
United States, Massachusetts
Boston, Massachusetts, United States
United States, Nevada
Las Vegas, Nevada, United States
United States, New York
Brooklyn, New York, United States
United States, North Carolina
Chapel Hill, North Carolina, United States
Winston Salem, North Carolina, United States
United States, Pennsylvania
Philadelphia, Pennsylvania, United States
United States, South Carolina
Columbia, South Carolina, United States
United States, Texas
Houston, Texas, United States
Buenos Aires, Argentina
Mar Del Plata N/A, Argentina
Neuquen, Argentina
Brisbane, Australia
Darlinghurst, Australia
Surry Hills, Australia
Westmead N/A, Australia
Wien, Austria
Brussels, Belgium
Gent, Belgium
Leuven, Belgium
Canada, British Columbia
Vancouver, British Columbia, Canada
Canada, Ontario
Ottawa, Ontario, Canada
Toronto, Ontario, Canada
Canada, Quebec
Montreal, Quebec, Canada
Providencia, Chile
Santiago, Chile
Costa Rica
Costa Rica, Costa Rica
San Jose, Costa Rica
Aalborg, Denmark
Copenhagen Ø, Denmark
Hvidovre, Denmark
Bobigny, France
Lyon, France
Nice, France
Orleans Cedex 2, France
Paris Cedex 12, France
Paris, France
Berlin, Germany
Erlangen, Germany
Freiburg, Germany
Hamburg, Germany
Köln, Germany
Mannheim, Germany
Munich, Germany
München, Germany
Athens, Greece
Guatemala, Guatemala
Sungai Buloh, Malaysia
Ciudad De Mexico, Mexico
Del Tlalpan, Mexico
Guadalajara N/A, Mexico
Mex Ctity, Mexico
Panama, Panama
Puerto Rico
San Juan, Puerto Rico
Russian Federation
Kazan, Russian Federation
Krasnodar, Russian Federation
Moscow N/A, Russian Federation
Saint-Petersburg, Russian Federation
Sint Petersburg, Russian Federation
Smolensk, Russian Federation
St Petersburg, Russian Federation
Volgograd, Russian Federation
Voronezh, Russian Federation
Singapore, Singapore
South Africa
Cape Town, South Africa
Dundee, South Africa
Johannesburg, South Africa
Pretoria, South Africa
Barcelona N/A, Spain
Barcelona, Spain
Zurich N/A, Switzerland
Taipei, Taiwan
Tiachung, Taiwan
Bangkok, Thailand
Chiang Mai, Thailand
Khon Kaen, Thailand
United Kingdom
Brighton, United Kingdom
London, United Kingdom
Sponsors and Collaborators
Tibotec Pharmaceuticals, Ireland
Study Director: Tibotec Pharmaceuticals Clinical Trial Tibotec Pharmaceutical Limited
  More Information

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Tibotec Pharmaceuticals, Ireland Identifier: NCT00258557     History of Changes
Other Study ID Numbers: CR002800
TMC114-C211 ( Other Identifier: Tibotec Pharmaceuticals, Ireland )
Study First Received: November 22, 2005
Last Updated: June 25, 2013

Keywords provided by Tibotec Pharmaceuticals, Ireland:
Anti-Retroviral agents
Treatment naïve patients

Additional relevant MeSH terms:
Protease Inhibitors
HIV Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents processed this record on March 29, 2017